MedPath

Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome

Not Applicable
Terminated
Conditions
Hyperventilation Syndrome
Interventions
Behavioral: Nasal breathing rehabilitation
Behavioral: Standard rehabilitation
Registration Number
NCT03159429
Lead Sponsor
University Hospital, Montpellier
Brief Summary

The main objective of this study is to measure the effect (at 3 months) of dyspnea control rehabilitation with nasal ventilation versus standard rehabilitation, in dyspneic patients with hyperventilation syndrome.

Detailed Description

Hyperventilation syndrome (SHV) is a complex disorder of adaptation of ventilation to exercise. This is a frequent reason for consultation because it is associated with major symptoms, which can be a source of sometimes heavy exploration and wandering. The breathless patient reduces his activity and enters the vicious circle of deconditioning. The principal clinical symptom in this pathology is the dyspnea with hypocapnia. The diagnosis is based on quality of life questionnaires and provocation tests, such as stress testing. When hypocapnia becomes chronic, a disturbance of breathing control sets in.

In SHV therapy, control of ventilation to exercise is recommended in the first line. It aims to slow the respiratory rate or tidal volume with, for example, techniques of voluntary hypoventilation and abdominal ventilation. But the evidence of literature is lacking to recommend a particular technique. Given the implication of the dysfunction of the nose, of non-unicist and often multifactorial origin in the respiratory pathologies, one of the possibilities of intervention is to reeducate the patient to the nasal ventilation.

Our rehabilitation of nasal ventilation is based on the clinical observation of hyperventilation dyspnea. During breathlessness breathing is essentially oral. It is a natural mechanism of adaptation that responds to the metabolic demand, which is far too present in the hyperventilation syndrome. From our therapeutic experience, the hypothesis is that the work on nasal ventilation can provide the necessary elements for the correction of SHV. The importance of the nasal breath in managing emotions and effort in sport is already considered.

This study will evaluate pathophysiological and clinical parameters effets of rehabilitation of nasal ventilation compared to those of the technique of voluntary hypoventilation (ThV) which is the conventional management of patients with SHV.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • The patient must have given his / her free and informed consent and signed the consent
  • The patient must be a member or beneficiary of a health insurance program
  • The patient is available for 3 months of follow-up
  • The patient has at least two of the following clinical symptoms consistent with hyperventilation sydrome: dyspnea, chest pain or pressure, visual blurring, dizziness, a sensation of abdominal swelling, tingling in the fingers, stiffness in the fingers or arms, tingling sensation around the mouth, cold or moist hands, tension or anxiety
  • Resting hypocapnia defined by a PaCO2 <38 mmHg and a normal O2 alveolo-arterial gradient D (A-a) O2
  • Absence of significant obstructive or restrictive pathology according to respiratory function tests
  • Absence of indirect signs of pulmonary arterial hypertension according to echocardiography
  • Absence of alteration of gas exchange on maximum cardiopulmonary stress test (elevation of gradient D (A-a) O2 > 35 mmHg at peak stress)
  • At least 2 of the following criteria: (i) a Nijmegen questionnaire score > 23, (ii) the recurrence of at least two common symptoms during the maximum cardiopulmonary stress test, (iii) delayed return of PETCO2 (partial pressure of end-tidal carbon dioxide) to its basal value (> 5 minutes)
Exclusion Criteria
  • The subject is participating in another study
  • The subject is in an exclusion period determined by a previous study
  • The subject is under judicial protection, or is an adult under any kind of guardianship
  • The subject refuses to sign the consent
  • It is impossible to correctly inform the subject
  • The subject cannot fluently read French
  • The patient is pregnant
  • The patient is breastfeeding
  • The subject has a contra-indication (or an incompatible drug association) for a treatment required during this study (a priori, there are no contra-indicated drugs)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Experimental armNasal breathing rehabilitationPatients randomized to this arm will participate in the new rehabilitation programme. Intervention: Nasal breathing rehabilitation
Comparator armStandard rehabilitationPatients randomized to this arm will participate in the usual rehabilitation programme. Intervention: Standard rehabilitation
Primary Outcome Measures
NameTimeMethod
Change in Dyspnea at VO2maxChange between Day 0 and Day 90 +- 30

Dyspnea measured at the first VO2max during a maximal cardio-pulmonary effort test. Dyspnea is measured using a visual analog scale.

Secondary Outcome Measures
NameTimeMethod
Ventilation during isoworkChange between Day 0 and Day 90 +- 30

(Ventilation equivalents V'E / V'O2 and V'E / V'CO2)

pH at maximum effortChange between Day 0 and Day 90 +- 30

pH at maximum effort

Transcutaneous oximetryChange between Day 0 and Day 90 +- 30

tcpO2

Distance walked during 6 minute walking testChange between Day 0 and Day 90 +- 30

Distance walked during 6 minute walking test

Maximum rate of oxygen consumptionChange between Day 0 and Day 90 +- 30

VO2max

Dyspnea threshold during exercise testingChange between Day 0 and Day 90 +- 30

Dyspnea is measured using visual analogue scales

the equation P0.1=f(PETCO2)Change between Day 0 and Day 90 +- 30

P0.1 = occlusion pressure; PETCO2 = end tidal carbon dioxide tension

SF36 questionnaire scoreChange between Day 0 and Day 90 +- 30

SF36 questionnaire score

Time to start of mouth-breathing during exercise testChange between Day 0 and Day 90 +- 30

The delay of onset of oral ventilation during walking and / or on ergocycle

The SNOT22 questionnaire scoreChange between Day 0 and Day 90 +- 30

The SNOT22 questionnaire score

PACO2 at restChange between Day 0 and Day 90 +- 30

PAC02 = Partial pressure of carbon dioxide in arterial blood

pH at restChange between Day 0 and Day 90 +- 30

pH at rest

PaO2 at maximum effortChange between Day 0 and Day 90 +- 30

PaO2 = Partial pressure of oxygen in arterial blood

Maximum dyspnea valuesChange between Day 0 and Day 90 +- 30

Dyspnea is measured using visual analogue scales

PETCO2 value when VE = 0Change between Day 0 and Day 90 +- 30

VE = expiratory ventilation ; PETCO2 = end tidal carbon dioxide tension

PaO2 at restChange between Day 0 and Day 90 +- 30

PaO2 = Partial pressure of oxygen in arterial blood

PACO2 at maximum effortChange between Day 0 and Day 90 +- 30

PAC02 = Partial pressure of carbon dioxide in arterial blood

Breathing rates during excerise testingChange between Day 0 and Day 90 +- 30

breaths per minute

The slope of the equation VE=f(PETCO2)Change between Day 0 and Day 90 +- 30

VE = expiratory ventilation ; PETCO2 = end tidal carbon dioxide tension

Dyspnea measured using the MRC scaleChange between Day 0 and Day 90 +- 30

Dyspnea measured using the Medical Research Council scale

Nijmegen questionnaire scoreChange between Day 0 and Day 90 +- 30

Nijmegen questionnaire score

VQ-11 questionnaire scoreChange between Day 0 and Day 90 +- 30

VQ-11 questionnaire score

HAD questionnaire scoreChange between Day 0 and Day 90 +- 30

HAD questionnaire score

Trial Locations

Locations (1)

Montpellier University Hospital

🇫🇷

Montpellier, France

© Copyright 2025. All Rights Reserved by MedPath